Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Trial of Afatinib (BIBW 2992) + Cetuximab in Advanced Solid Tumours

Phase 1

Completed

Conditions: Neoplasms

Interventions: Drug: Cetuximab( erbitux®)
Drug: Afatinib

First Posted Date: 2013-12-25

Last Posted Date: 2017-06-22

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 58

Registration Number: NCT02020577

Locations: 🇫🇷
1200.122.33001 Boehringer Ingelheim Investigational Site, Villejuif Cedex, France
🇪🇸
1200.122.34001 Boehringer Ingelheim Investigational Site, Madrid, Spain

Investigation of Potential Drug-drug Interactions Between Faldaprevir and the Immunosuppressant Drugs Cyclosporine or Tacrolimus

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Faldaprevir
Drug: Cyclosporine
Drug: Tacrolimus

First Posted Date: 2013-12-20

Last Posted Date: 2016-05-23

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 32

Registration Number: NCT02016625

Locations: 🇩🇪
1241.61.1 Boehringer Ingelheim Investigational Site, Mannheim, Germany

Multiple Rising Does Study (Subcutaneous Doses) of BI 655064 in Male and Female Patients With Chronic Primary Immune Thrombocytopenic Purpura (ITP).

Phase 1

Terminated

Conditions: Purpura, Thrombocytopenic, Idiopathic

Interventions: Drug: BI 655064

First Posted Date: 2013-12-12

Last Posted Date: 2024-03-15

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 6

Registration Number: NCT02009761

Locations: 🇺🇸
University of Southern California, Los Angeles, California, United States
🇺🇸
New York Hospital, Cornell Medical Center, New York, New York, United States

Tiotropium+Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 2)

Phase 3

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: tiotropium
Drug: placebo
Drug: olodaterol

First Posted Date: 2013-12-10

Last Posted Date: 2016-01-20

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 809

Registration Number: NCT02006732

Locations: 🇺🇸
1237.26.10613 Boehringer Ingelheim Investigational Site, St. Louis, Missouri, United States
🇺🇸
1237.26.10606 Boehringer Ingelheim Investigational Site, Medford, Oregon, United States
🇦🇺
1237.26.61004 Boehringer Ingelheim Investigational Site, Concord, New South Wales, Australia

and more 75 locations

Volasertib + Decitabine in Patients With Acute Myeloid Leukemia (AML)

Phase 1

Terminated

Conditions: Leukemia, Myeloid, Acute

Interventions: Drug: decitabine iv
Drug: volasertib iv infusion

First Posted Date: 2013-12-06

Last Posted Date: 2019-01-31

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 13

Registration Number: NCT02003573

Locations: 🇺🇸
Yale Cancer Center, New Haven, Connecticut, United States
🇺🇸
Washington School of Medicine, Saint Louis, Missouri, United States
🇺🇸
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Efficacy and Safety of Empagliflozin Versus Sitagliptin in Patients With Type 2 Diabetes

Phase 3

Withdrawn

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Sitagliptin
Drug: Empagliflozin
Drug: Placebo

First Posted Date: 2013-11-14

Last Posted Date: 2014-10-27

Lead Sponsor: Boehringer Ingelheim

Registration Number: NCT01984606

Effect of Food and Increased Gastric pH Value on Bioavailability of a Single Dose of BI 207127 in Healthy Caucasian and Japanese Subjects

Phase 1

Terminated

Conditions: Healthy

Interventions: Drug: BI 207127
Drug: BI 207127 low fat
Drug: BI 207127 with Omeprazole
Drug: BI 207127 high fat

First Posted Date: 2013-11-14

Last Posted Date: 2016-05-16

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 16

Registration Number: NCT01983566

Locations: 🇩🇪
1241.44.49001 Boehringer Ingelheim Investigational Site, Neuss, Germany

Nintedanib Twice Daily vs Placebo in Patients Diagnosed With Idiopathic Pulmonary Fibrosis (IPF)

Phase 3

Completed

Conditions: Idiopathic Pulmonary Fibrosis

Interventions: Drug: Matching Placebo
Drug: Nintedanib

First Posted Date: 2013-11-08

Last Posted Date: 2018-04-17

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 113

Registration Number: NCT01979952

Locations: 🇨🇦
St. Paul's Hospital, Vancouver, British Columbia, Canada
🇨🇦
QEII Health Sciences Centre (Dalhousie University), Halifax, Nova Scotia, Canada
🇺🇸
Lowcountry Lung and Crit Care, Charleston, South Carolina, United States

and more 22 locations

Add-on to Micamlo BP Trial

Phase 3

Completed

Conditions: Hypertension

Interventions: Drug: Telmisartan + amlodipine
Drug: Placebo
Drug: hydrochlorothiazide

First Posted Date: 2013-11-03

Last Posted Date: 2016-11-29

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 309

Registration Number: NCT01975246

Locations: 🇯🇵
1348.1.022 Boehringer Ingelheim Investigational Site, Mihama-ku, Chiba, Chiba, Japan
🇯🇵
1348.1.004 Boehringer Ingelheim Investigational Site, Miyagino-ku, Sendai, Miyagi, Japan
🇯🇵
1348.1.025 Boehringer Ingelheim Investigational Site, Sapporo, Hokkaido, Japan

and more 27 locations

Relative Bioavailability of 2 Fixed Dose Combinations of Empagliflozin/Metformin Compared With Single Tablets

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Empagliflozin/Metformin XR, FDC
Drug: Empagliflozin/Metformin XR FDC
Drug: 25 mg Empagliflozin/1000 mg Metformin XR, FDC
Drug: 1 tablet Empagliflozin/3 tablets Metformin XR
Drug: 1 tablet Empagliflozin/2 tablets Metformin XR

First Posted Date: 2013-11-03

Last Posted Date: 2017-03-08

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 72

Registration Number: NCT01975220

Locations: 🇺🇸
1276.13.1 Boehringer Ingelheim Investigational Site, Austin, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy